At the 2018 ASCO conference, the results of a study on chemotherapy attracted a lot of attention. Studies have shown that an innovative chemotherapy can effectively treat pancreatic cancer known as the “king of cancer”. For this cancer with a very poor prognosis, this chemotherapy can actually prolong the life of the patient for up to 20 months!
In orci iudicium vocatur prodige XXIV / CCTG PA.24 et inquisitores recruited numerus aegris cum non-ductus pancreatis; metastatic ADENOCARCINOMA (PDAC), quod ductum pancreaticum cancer est etiam maxime communi, ratio XC% of casibus omnibus. %. His aegris habent surgery perpessa tollere id malum temptent. In 3-12 septimanas post manu, a totalis de aegris cum CDXCIII circulos passim dividitur in duo, unum coetus accepit gemcitabine (gemcitabine) curatio, alter novus coetus accepit chemotherapy mFOLFIRINOX (FOLFIRINOX mutatio) curatio. Hi quatuor continet chemotherapy diversis components, inter oxaliplatin, leucovorin, irinotecan et Fluorouracil-V.
In studium ostendit quod cum medianus sequantur, ex 33.6 menses morbo-liberum salvos aegris in media coetus mFOLFIRINOX erat signanter superior quam in gemcitabine coetus (21.6 menses, menses 12.8). Mediana in terms of altiore salvos est, illud uero prior et altior quam XX mensibus (20 54.4 menses, menses). Cum autem salvos additional beneficia, potest etiam ex parte effectus chemotherapy regi imperio.
Secundum ad consilium, quod inquisitores et permanere ad explorandum optimum tempus chemotherapy ut intelligere, num aegris potest accipere chemotherapy ante surgery Dominus taedere super summo tumore effundunt, per reducendo periculo tumore micrometastasis atque augendae potentiae cum optimus quisque summo tumore effundunt quod totaliter remotum a surgery. Expectamus bonum nuntium haec potius de iis rebus de pancreaticum cancer aegros passus a sede Lorem et spem.
